Luca Arecco, Clinical Research Fellow at ESMO, shared on X:
“The anti-HER2 and ADCs landscape keeps expanding.
Cristina Saurara views current indications and how these agents are reshaping treatment across HER2 positive BC.”
Other articles about breast cancer on OncoDaily.